Amide substituted imidazoquinolines

A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (Ib):

• wherein
• R1 is —C2-4 alkyl-NR3—CO—R4 wherein R4 is heterocyclyl which may be unsubstituted or substituted by one or more substituents selected from the group consisting of:
• -alkyl;
• -alkenyl;
• -alkynyl,
• -(alkyl)0-1-aryl;
• -(alkyl)0-1-(substituted aryl);
• -(alkyl)0-1-heterocyclyl;
• -(alkyl)0-1-(substituted heterocycyl);
• -(alkyl)0-1-heteroaryl;
• -(alkyl)0-1-(substituted heteroaryl);
• —O-alkyl;
• —O-(alkyl)0-1-aryl;
• —O-(alkyl)0-1-(substituted aryl);
• —O-(alkyl)0-1-heterocyclyl;
• —O-(alkyl)0-1-(substituted heterocyclyl);
• —O-(alkyl)0-1-heteroaryl;
• —O-(alkyl)0-1-(substituted heteroaryl);
• —CO-aryl;
• —CO-(substituted aryl);
• —CO-heteroaryl;
• —CO-(substituted heteroaryl);
• —COOH;
• —CO—O-alkyl;
• —CO-alkyl;
• —S(O)0-2-alkyl;
• —S(O)0-2-(alkyl)0-1-aryl;
• —S(O)0-2-(alkyl)0-1-(substituted aryl);
• —S(O)0-2-(alkyl)0-1-heterocyclyl;
• —S(O)0-2-(alkyl)0-1-(substituted heterocyclyl);
• —S(O)0-2-(alkyl)0-1-heteroaryl;
• —S(O)0-2-(alkyl)0-1-(substituted heteroaryl);
• —P(O)(OR3)2;
• —NR3—CO—O-alkyl;
• —N3;
• -halogen;
• —NO2;
• —CN;
• -haloalkyl;
• —O-haloalkyl;
• —CO-haloalkyl;
• —OH;
• —SH;
• or R4 is
• wherein R5 is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group;
• R2 is selected from the group consisting of:
• -hydrogen;
• -alkyl;
• -alkenyl;
• -aryl;
• -(substituted aryl);
• -heteroaryl;
• -(substituted heteroaryl);
• -heterocyclyl;
• -(substituted heterocyclyl);
• -alkyl-O-alkyl;
• -alkyl-O-alkenyl;
• and
• -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
• —OH;
• -halogen;
• —N(R3)2;
• —CO—N(R3)2;
• —CO—C1-10alkyl;
• —CO—O—C1-10alkyl;
• —N3;
• -aryl;
• -(substituted aryl);
• -heteroaryl;
• -(substituted heteroaryl);
• -heterocyclyl;
• -(substituted heterocyclyl);
• —CO-aryl;
• and
• —CO-heteroaryl;
• each R3 is independently selected form the group consisting of hydrogen;
• C1-10alkyl-heteroaryl;
• C1-10alkyl-(substituted heteroaryl);
• C1-10alkyl-aryl;
• C1-10alkyl-(substituted aryl) and C1-10alkyl;
• n is 0 to 4;
• and each R present is independently selected from the group consisting of C1-10 alkyl, C1-10alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.